Health & MedicineBreaking NewsBreakingLatest News
US FDA Approves New Hepatitis B Drug That Could Help Patients Achieve Functional Cure
Sentiment: PositiveHigh Priority
What Happened?
The US FDA has approved Hibsago (bepirovirsen) for chronic hepatitis B, allowing some patients to control the virus after stopping antiviral medications. This marks a significant advancement in treatment options.
Key points
- Hibsago is the first FDA-approved antisense oligonucleotide for chronic hepatitis B.
- The drug was approved on October 20, 2026, after Japan's initial approval in August 2026.
- 24% of patients on Hibsago were able to stop their antiviral treatment compared to none on placebo.
- The drug is administered as weekly injections for up to 24 weeks.
- Hibsago targets the hepatitis B virus's genetic material to help the immune system control the infection.
Key insights
- Hibsago may lead to a significant reduction in long-term liver complications for patients.
- The treatment offers a new pathway for patients who have struggled with existing antiviral therapies.
- Patients must meet specific criteria to be eligible for Hibsago, emphasizing the need for personalized treatment.
Why it matters
This approval could provide new hope for chronic hepatitis B patients seeking better treatment options.
Tags
Entities
Hibsago· ProductFDA· OrganizationGSK plc· CompanyIonis· CompanyJapan· Country
Source
Times Now
